Company intelligence / Profile preview

Caladan Bio

Brooklyn, New York, United Statescaladan.bio ↗

Ownership: Private
Development stage: Other

Overview

Caladan Bio has developed the "Caladan 250," a modular benchtop bioreactor system that integrates advanced sensors and intuitive no-code software to automate and accelerate high-throughput biological experiments. Their platform enables synthetic biology and biomanufacturing teams to run more parallel experiments at lower cost, generating standardized datasets suitable for AI/ML-driven process optimization. The company recently raised $5 million in seed funding to expand its team and pilot installations with industry partners.

Modalities: DeviceSoftware (for bioprocess automation)
Industry: Drug Discovery Services

Partnerships

Pilot partnerships with synthetic biology companies expected in 2024–2025

Beyond the preview

Go deeper on Caladan Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Caladan Bio.

Explore the full profile